The newest pain killer, as of November 2018, is Dsuvia.
Dsuvia: A New Opioid for Acute Pain Management
The Food and Drug Administration (FDA) approved Dsuvia on November 2, 2018. This new opioid is specifically intended for managing acute pain in adults.
Key Characteristics of Dsuvia:
- Purpose: Dsuvia is designed for short-term use to treat acute pain.
- Class: It is classified as an opioid, which means it carries risks associated with this drug class, including addiction and misuse.
- Administration: The drug is administered sublingually.
- Target Patients: It is intended for adult use only.
- Approval Date: Approved by FDA on November 2, 2018.
Important Considerations:
- Opioid Risks: As an opioid, Dsuvia has risks of misuse, addiction, and overdose. These potential risks should be considered when using this drug.
- Prescription: It can only be obtained via prescription from a healthcare provider.
- Not for Chronic Pain: Dsuvia is not recommended for long-term or chronic pain.
In conclusion, Dsuvia is a recently FDA-approved pain killer designed to manage acute pain in adults. It is important to note that it is an opioid and carries associated risks.
